Bharat Biotech Achieves 98% Audit Readiness with Pharmaceutical eQMS Platform

Bharat Biotech International Limited is a pioneering Indian biotechnology company best known for developing COVAXIN, India's first indigenous COVID-19 vaccine. With vaccine manufacturing operations conducted under stringent WHO GMP guidelines and multiple regulatory authorities' oversight, maintaining a consistently high level of quality management is a non-negotiable requirement for every batch released for human use.

AmpleLogic's eQMS platform was implemented across Bharat Biotech's manufacturing sites to unify quality event management, CAPA tracking, change control, and risk management processes. The biological manufacturing environment required specialized workflows that accounted for sterility considerations, environmental monitoring, and biosafety containment — all of which were configured into the platform's flexible workflow engine.

The system's real-time dashboards provided quality directors with an integrated view of quality performance across all sites, enabling trend identification that would have been invisible in siloed systems. Automated escalation workflows ensured that critical quality events received attention within defined timelines, and the comprehensive audit trail documentation met both FDA and EMA inspection requirements.

Bharat Biotech achieved 98% audit readiness — a remarkable standard for an organization operating under simultaneous oversight from multiple global regulatory bodies. The eQMS platform became the backbone of Bharat Biotech's quality infrastructure, supporting their ambition to be a trusted global vaccine supplier and enabling rapid scale-up during the COVID-19 pandemic response.